<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2017.73012</article-id><article-id pub-id-type="publisher-id">WJCR-21124</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20170300000_15033908.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  白血病诱导分化剂的研究进展
  Research Progress of Leukemia Induced Differentiation Agents
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>鑫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>海英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>卫国</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南华大学肿瘤研究所，湖南 衡阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>hwg_doctor@126.com(黄卫)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>06</month><year>2017</year></pub-date><volume>07</volume><issue>03</issue><fpage>75</fpage><lpage>80</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   诱导分化具有选择性高、副作用小、疗效好等优点。诱导分化机制的研究的深入推动着诱导分化治疗白血病的研究和发展，使其有望成为将来治疗白血病的主要手段。近年来，急性早幼粒细胞白血病的诱导分化治疗已成为目前血液学研究的热点之一，并且国内外对白血病的诱导分化治疗的研究取得了一定的成果。本文对近年来白血病诱导分化的新型诱导分化剂，如：维甲酸类、砷剂、中药类、分子靶向治疗药物类、去甲基化药物类、组蛋白酶去乙酰化药物、miRNA类等的使用与分子机制进行了总结，有利于了解诱导分化剂的研究新进展。 Differentiation has the advantages such as highly-selective, low side effect and good curative effect. The further study of differentiation mechanism propels the study and development of treating leukemia by differentiation, and makes it the main method of treating leukemia in the future. In recent years, the differentiation therapy of acute promyelocytic leukemia has become one of the hot points of hematology research, and there has achieved some degree of success in the differentiation therapy of leukemia at home and abroad. This paper summarizes the commonly used and molecular mechanism of differentiation induced agents in recent years, such as, dimension of formic acid, arsenic, traditional Chinese medicine, molecular target drugs, demethylating drugs, acetylating drugs and miRNAs. It is helpful to understand the new progress of differentiation.
    
  
 
</p></abstract><kwd-group><kwd>白血病，诱导分化，诱导分化剂, Leukemia</kwd><kwd> Differentiation</kwd><kwd> Differentiation Induced Agent</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>白血病诱导分化剂的研究进展<sup> </sup></title><p>江伟，邓鑫，李海英，黄卫国<sup>*</sup></p><p>南华大学肿瘤研究所，湖南 衡阳</p><disp-formula id="hanspub.21124-formula23"><graphic xlink:href="http://html.hanspub.org/file/2-2150111x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年6月7日；录用日期：2017年6月24日；发布日期：2017年6月27日</p><disp-formula id="hanspub.21124-formula24"><graphic xlink:href="http://html.hanspub.org/file/2-2150111x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>诱导分化具有选择性高、副作用小、疗效好等优点。诱导分化机制的研究的深入推动着诱导分化治疗白血病的研究和发展，使其有望成为将来治疗白血病的主要手段。近年来，急性早幼粒细胞白血病的诱导分化治疗已成为目前血液学研究的热点之一，并且国内外对白血病的诱导分化治疗的研究取得了一定的成果。本文对近年来白血病诱导分化的新型诱导分化剂，如：维甲酸类、砷剂、中药类、分子靶向治疗药物类、去甲基化药物类、组蛋白酶去乙酰化药物、miRNA类等的使用与分子机制进行了总结，有利于了解诱导分化剂的研究新进展。</p><p>关键词 :白血病，诱导分化，诱导分化剂</p><disp-formula id="hanspub.21124-formula25"><graphic xlink:href="http://html.hanspub.org/file/2-2150111x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>白血病是一类造血干细胞恶性克隆性疾病，俗称“血癌”。白血病细胞因为增殖失控、分化障碍、凋亡受阻等机制在骨髓和其他组织中大量增殖累积，并浸润其他组织和器官，同时正常造血受抑制。白血病在我国各地区的各种肿瘤中的发病率排第六位，是当今我国十大高发恶性肿瘤之一。而人类白血病的发病原因与机制尚不完全清楚，目前认为其可能与以下几个方面有关：1) 免疫功能异常、病毒感染等生物因素。2) 电离辐射等物理因素。3) 乙双吗啉、苯等化学因素。4) 遗传因素。5) 由淋巴瘤、骨髓增生异常综合征等其他血液疾病转变而来。化疗是肿瘤治疗最常见的方法，传统的白血病治疗多采用化疗，但这种方法注重的是杀伤细胞进而抑制增殖，通常在杀伤白血病细胞的同时对正常的造血功能产生抑制，具有选择性差、容易出现耐药性、副作用大的缺点 [<xref ref-type="bibr" rid="hanspub.21124-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.21124-ref2">2</xref>] ，在临床上的应用范围有限。</p><p>由于化疗治疗白血病的效果不甚理想，近年来出现了的诱导分化治疗为白血病的治疗开辟了一条新的途径。诱导分化是通过诱导分化剂促使分化不完全的肿瘤细胞分化成熟，使恶性肿瘤向良性转化。近年来出现的诱导分化等新的治疗方法，具有副作用小，疗效较好等特点 [<xref ref-type="bibr" rid="hanspub.21124-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.21124-ref4">4</xref>] 。全反式维甲酸、三氧化二砷、苦参碱、地西他滨、Trichostatin A.等在诱导分化治疗上有着不错的疗效，具有较高的缓解率，较好的预后和较低的复发率。而更多高效、低毒、高选择性的诱导分化剂则有待进一步地去探索。寻找和发现新的诱导分化剂是目前白血病诱导分化治疗的重点，本文对近年来白血病诱导分化治疗常用及新型诱导分化剂进行了初步的归纳总结如下。</p></sec><sec id="s4"><title>2. 维甲酸类</title><p>在已发现的大量诱导分化剂中，诱导分化效果比较好且已经用于临床治疗白血病的是维甲类。维甲类包括各种衍生物，如维甲醇、维甲醛和维甲酸(RA)及其众多的合成衍生物包括维胺酸和维胺脂等。维甲酸对人体有多种功效，有研究表明 [<xref ref-type="bibr" rid="hanspub.21124-ref5">5</xref>] ，维甲酸对急性粒细胞性白血病(APL)的治疗有诱导分化的作用。而我国学者在国际上率先成功地应用全反式维甲酸(ATRA)治疗APL，不仅完全缓解率极高，而且可避免弥漫性血管内凝血(DIC)发生，对骨髓无抑制作用，对病人的致死率低，并且结合其他药物使用会有更好的疗效，开创了一种全新的治疗APL的方法，即诱导分化治疗 [<xref ref-type="bibr" rid="hanspub.21124-ref6">6</xref>] 。由于其有着使用方便，费用低廉等优点，ATRA被认为是目前诱导治疗APL的首选药物。</p><p>虽然维甲类是治疗APL的首选药，但临床上往往不会单独使用维甲酸来治疗APL，因为单用维甲酸治疗白血病缓解维持的时间短，且易复发，所以目前治疗APL多联合一些其他疗法或联合一些其他试剂治疗。比如，ATRA联合传统化疗治疗。ATRA联合As<sub>2</sub>O<sub>3</sub>治疗，ATRA联合阿糖胞苷治疗，ATRA联合干扰素治疗等 [<xref ref-type="bibr" rid="hanspub.21124-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.21124-ref8">8</xref>] 。</p></sec><sec id="s5"><title>3. 砷剂</title><p>最近的研究已显示，砷剂复合物(包括As<sub>2</sub>O<sub>3</sub>, As<sub>4</sub>S<sub>4</sub>)具有治疗APL的效果。有学者在对耐维甲酸APL细胞株的研究中发现三氧化二砷和ATRA的治疗共同靶点是PML-RARα融合蛋白 [<xref ref-type="bibr" rid="hanspub.21124-ref9">9</xref>] ，均通过直接或间接激活维甲酸受体相关信号途径而诱导APL分化，表明两种药物具有协同促分化作用，且不存在交叉耐药性，能够相互促进对细胞作用敏感性，所以在两者联合用药治疗白血病时能产生较好的效果 [<xref ref-type="bibr" rid="hanspub.21124-ref10">10</xref>] 。除与ATRA联合用药外，As<sub>2</sub>O<sub>3</sub>还能与阿糖胞苷联合用药。As<sub>2</sub>O<sub>3</sub>联合阿糖胞苷治疗APL临床缓解率高，诱导缓解过程平稳，副作用较小 [<xref ref-type="bibr" rid="hanspub.21124-ref11">11</xref>] 。值得注意的是，砷剂具有毒性，当人体摄入超量As<sub>2</sub>O<sub>3</sub>时，会引起急慢性中毒，甚至死亡或是其他器官的癌症，如膀胱癌，肝癌，肾癌等 [<xref ref-type="bibr" rid="hanspub.21124-ref12">12</xref>] 。因此，使用As<sub>2</sub>O<sub>3</sub>治疗APL要控制其剂量在低毒范围内。</p></sec><sec id="s6"><title>4. 中药类</title><p>中医药有着高效、多靶点、低毒、效果明确，且不会使肿瘤细胞产生耐药性的优点，在诱导分化治疗白血病中有着很大的发展潜力。在最新的研究中，发现下列多种中药具有抗肿瘤的作用：藤黄、砷剂、冬凌草、蛇床子、汉防己甲素、姜黄素、黄芩、通关藤、南蛇藤、人参皂苷、三七总皂苷、和厚朴酚、补骨脂素、毒蒿素、苦参碱、大黄素、半枝莲灵芝等。其各种药物作用机制互不相同，且具有逆转肿瘤细胞多药耐药性的作用。</p><p>在诱导肿瘤细胞分化的作用上，人参皂苷Rh2可作用于B16细胞，可增加其黑色素的生成能力，使形态向正常细胞分化，逐渐转化为正常细胞 [<xref ref-type="bibr" rid="hanspub.21124-ref13">13</xref>] 。黄芩苷可作用于Bel-7402细胞，使甲胎蛋白减少，γ-谷氨酸转肽酶比活降低，ALB分泌显著提高。细胞内CAMP含量升高。苦参碱能在细胞增殖时期对肿瘤细胞产生抑制作用，从而抑制其增生 [<xref ref-type="bibr" rid="hanspub.21124-ref14">14</xref>] 。人参多糖可通过对Wnt/beta-catenin信号通路阻碍作用于CNE-2细胞，显著抑制其增殖，并诱导其凋亡 [<xref ref-type="bibr" rid="hanspub.21124-ref15">15</xref>] 。</p><p>而在临床医用方面，苦参碱的临床应用已经进入了起步阶段。据报道，在一些研究中发现苦参碱可强效抑制AML细胞在人体内增殖并诱导其凋亡 [<xref ref-type="bibr" rid="hanspub.21124-ref16">16</xref>] 。另一些研究发现苦参碱结合全反式维甲酸可以增加细胞内环腺苷酸的水平和蛋白激酶A的活性，并降低端粒酶的活性从而达到治疗诱导分化治疗白血病的目的 [<xref ref-type="bibr" rid="hanspub.21124-ref17">17</xref>] ，并且苦参碱联合全反式维甲酸用药时比单用苦参碱时疗效更好。这说明苦参碱在临床治疗白血病中，有着非常重要的作用。</p><p>用中药治疗白血病的作用常被人们低估，以目前的研究来看，足以说明应用中药治疗白血病的潜力是巨大的。</p></sec><sec id="s7"><title>5. 分子靶向治疗药物类</title><p>分子靶向治疗相比于传统的化疗它具有疗效明显、特异性强、较少损伤正常组织等优点。根据药物分子的大小可将其分为大分子单克隆抗体类和小分子化合物类。在大分子单克隆抗体类中，可分作用于细胞膜分化相关抗原的抗肿瘤单克隆抗体，作用于表皮生长因子受体的抗肿瘤单克隆抗体几类。其目前用于临床治疗的药物主要有利妥昔单抗、替伊莫单抗、帕尼单抗、吉妥珠单抗、阿莱珠单抗、贝伐单抗、曲妥珠单抗、托西莫单抗、西妥昔单抗等 [<xref ref-type="bibr" rid="hanspub.21124-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.21124-ref19">19</xref>] 。</p><p>而小分子化合物药类可分为单一靶点的抗肿瘤小分子化合物类，多靶点抗肿瘤的小分子化合物类。其主要的药物有甲磺酸伊马替尼、舒尼替尼、吉非替尼、范德它尼、厄洛替尼、拉帕提尼、索拉非尼等 [<xref ref-type="bibr" rid="hanspub.21124-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.21124-ref21">21</xref>] 。</p><p>肿瘤分子靶向治疗以肿瘤组织或细胞存在的特异性结构分子为靶点，利用一些具有特异结合特性的抗体和配合与靶点结合，从而达到直接治疗或导向治疗的目的的一类方法 [<xref ref-type="bibr" rid="hanspub.21124-ref22">22</xref>] 。</p><p>靶向治疗虽然具有特异性强，疗效明显等优点，但肿瘤发病机制非常复杂，在其生长过程中，随时可能产生基因突变，而导致靶向分子药物作用失效。此外，单一靶点的靶向分子药并不能完全抑制肿瘤的发展，只能对其中一部分的肿瘤细胞产生抑制作用。因此，多靶点抗肿瘤的靶向分子在诱导分化治疗中有着更加重要的作用。但联合用药的最佳模式和机制也不甚清楚，仍需要试验来做更多的研究。</p></sec><sec id="s8"><title>6. 去甲基化药物类</title><p>DNA甲基化改变是人类肿瘤最常见的表观遗传学改变 [<xref ref-type="bibr" rid="hanspub.21124-ref23">23</xref>] 。去甲基化类药物的作用即是使DNA的甲基化消失而使肿瘤细胞去除肿瘤细胞的特性，逐渐向正常细胞转变。此疗法对人体危害较小，且对耐药和复发的白血病患者有一定的疗效。</p><p>在近年的研究中，研究发现，DNA甲基化与人类慢性粒细胞白血病有着重要的关联 [<xref ref-type="bibr" rid="hanspub.21124-ref24">24</xref>] 。既然甲基化与白血病的发育有重要关联，那么去甲基化就成为了一种治疗白血病的新方法。体外实验和临床研究表明，甲基化是可以逆转的。去甲基化治疗主要使用药物来治疗。而目前去甲基化药物主要为地西他滨，又称5-杂氮-2’-脱氧胞苷，是一种2’-脱氧胞苷类似物。在各种临床研究中，地西他滨显示出了其治疗白血病的优势 [<xref ref-type="bibr" rid="hanspub.21124-ref25">25</xref>] 。但是由于目前对白血病的治疗大多集中在化疗上，关于去甲基化治疗白血病的研究很少，其他去甲基化药物仍处于临床前试验阶段。</p></sec><sec id="s9"><title>7. 组蛋白酶去乙酰化药物</title><p>目前的研究中，发现很多肿瘤细胞中组蛋白呈现低乙酰化的状态 [<xref ref-type="bibr" rid="hanspub.21124-ref26">26</xref>] 。且组蛋白乙酰化状态失衡与肿瘤发生有着比较密切的联系。肿瘤细胞中乙酰化与去乙酰化失衡而使细胞内组蛋白多数呈现低乙酰化的状态，导致肿瘤的形成。因此，使用去乙酰化抑制剂(HDACi)降低去乙酰化的水平而使乙酰化与去乙酰化达到一个新的平衡便成为治疗白血病的一种新的方法 [<xref ref-type="bibr" rid="hanspub.21124-ref27">27</xref>] 。</p><p>有研究表明，一些新型的HDACs抗癌药物如SAHA, TSA有诱导子宫内膜腺癌细胞分化的作用。目前，SAHA已投入临床使用，对耐药性肿瘤有较好的疗效 [<xref ref-type="bibr" rid="hanspub.21124-ref28">28</xref>] 。TrichostatinA (TSA)具有选择性，可选择性抑制HDACs [<xref ref-type="bibr" rid="hanspub.21124-ref29">29</xref>] ，使组蛋白乙酰化水平提高，而且其与紫杉醇联合使用能使紫杉醇对肿瘤细胞的抑制率升高。</p><p>虽然部分HDACi已投入临床使用，且有着不错的疗效，但如何使其发挥更大疗效作用，需要进一步的研究。总体上来说，HDACi的高效性和低毒性已展现了它治疗肿瘤的巨大优势。相信在不久的将来，HDACi的研究就会有巨大的突破。</p></sec><sec id="s10"><title>8. miRNA类</title><p>miRNA是一类长度为18~22个核苷酸的单链RNA分子，它对基因表达有着重要的作用。miRNA通过与靶基因mRNAs以不完全互补的方式结合诱导类似RNA干扰通路，从而在转录后水平调控基因表达 [<xref ref-type="bibr" rid="hanspub.21124-ref30">30</xref>] 。</p><p>目前miRNA的研究主要集中在急性淋巴细胞性白血病、慢性淋巴细胞性白血病、急性髓系白血病几类白血病上，且有着不错的疗效 [<xref ref-type="bibr" rid="hanspub.21124-ref31">31</xref>] 。而miRNA如何影响白血病发展，靶向何种基因，如何调控基因的表达仍在研究中，但miRNA具有很好的发展前景，很有可能成为未来治疗白血病的方向，这都需要今后不断的努力。</p></sec><sec id="s11"><title>9. 总结与展望</title><p>虽然目前用诱导分化疗法治疗白血病已取得了部分成功，但大多数都是治疗APL，且以ATRA、As<sub>2</sub>O<sub>3</sub>的研究及应用为多，而且很多诱导分化的机理也并不十分清楚，对一些诱导分化产生的副作用也未能得到解决 [<xref ref-type="bibr" rid="hanspub.21124-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.21124-ref33">33</xref>] 。另外如何更高效地联合用药，更好地联合传统化疗来治疗白血病仍处于研究之中。相信这一系列的问题都能在不久的将来取得突破性的进展。</p></sec><sec id="s12"><title>基金项目</title><p>中国博士后基金(2012M521528)，湖南省教育厅开放创新平台基金(15K109)衡阳市科技项目(2010KJ16)，南华大学研究生开放创新课题(2015XCX37)。</p></sec><sec id="s13"><title>文章引用</title><p>江 伟,邓 鑫,李海英,黄卫国. 白血病诱导分化剂的研究进展Research Progress of Leukemia Induced Differentiation Agents[J]. 世界肿瘤研究, 2017, 07(03): 75-80. http://dx.doi.org/10.12677/WJCR.2017.73012</p></sec><sec id="s14"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.21124-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.H. (2015) Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance. Pediatrics &amp; Neonatology, 56, 287. &lt;br&gt;https://doi.org/10.1016/j.pedneo.2014.10.006</mixed-citation></ref><ref id="hanspub.21124-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hegyi, B., Komaromi, I., Nanasi, P.P., et al. (2013) Selectivity Problems with Drugs Acting on Cardiac Na(+) and Ca(2)(+) Channels. Current Medicinal Chemistry, 20, 2552-2571. &lt;br&gt;https://doi.org/10.2174/09298673113209990123</mixed-citation></ref><ref id="hanspub.21124-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Etxabe, A., Lara-Castillo, M.C., Cornet-Masana, J.M., et al. (2017) Inhibition of Serotonin Receptor Type 1 in Acute Myeloid Leukemia Impairs Leukemia Stem Cell Functionality: A Promising Novel Therapeutic Target. Leukemia.  
&lt;br&gt;https://doi.org/10.1038/leu.2017.52</mixed-citation></ref><ref id="hanspub.21124-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Guo, J., Russell, E.G., Darcy, R., et al. (2017) Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. Molecular Pharmacology, 14, 940-952.  
&lt;br&gt;https://doi.org/10.1021/acs.molpharmaceut.6b01150</mixed-citation></ref><ref id="hanspub.21124-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, G. (2013) Novel Treatment of Acute Promyelocytic Leukemia: As(2)O(3), Retinoic Acid and Retinoid Pharmacology. Current Pharmaceutical Biotechnology, 14, 849-858. &lt;br&gt;https://doi.org/10.2174/1389201015666140113095812</mixed-citation></ref><ref id="hanspub.21124-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mi, J.Q., Li, J.M., Shen, Z.X., et al. (2012) How to Manage Acute Promyelocytic Leukemia. Leukemia, 26, 1743-1751.  
&lt;br&gt;https://doi.org/10.1038/leu.2012.57</mixed-citation></ref><ref id="hanspub.21124-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Abla, O. and Ribeiro, R.C. (2014) How I Treat Children and Adolescents with Acute Promyelocytic Leukaemia. British Journal of Haematology, 164, 24-38. &lt;br&gt;https://doi.org/10.1111/bjh.12584</mixed-citation></ref><ref id="hanspub.21124-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Fredly, H., Ersvaer, E., Kittang, A.O., et al. (2013) The Combination of Valproic Acid, All-Trans Retinoic Acid and Low-Dose Cytarabine as Disease-Stabilizing Treatment in Acute Myeloid Leukemia. Clinical Epigenetics, 5, 13.  
&lt;br&gt;https://doi.org/10.1186/1868-7083-5-13</mixed-citation></ref><ref id="hanspub.21124-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lo-Coco, F. and Hasan, S.K. (2014) Understanding the Molecular Pathogenesis of Acute Promyelocytic Leukemia. Best Practice &amp; Research Clinical Haematology, 27, 3-9. &lt;br&gt;https://doi.org/10.1016/j.beha.2014.04.006</mixed-citation></ref><ref id="hanspub.21124-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yanada, M., Tsuzuki, M., Fujita, H., et al. (2013) Phase 2 Study of Arsenic Trioxide Followed by Autologous Hematopoietic Cell Transplantation for Relapsed Acute Promyelocytic Leukemia. Blood, 121, 3095-3102.  
&lt;br&gt;https://doi.org/10.1182/blood-2012-11-466862</mixed-citation></ref><ref id="hanspub.21124-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Rehman, K. and Naranmandura, H. (2013) Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects. Current Drug Metabolism, 14, 1029-1041.</mixed-citation></ref><ref id="hanspub.21124-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wilcox, D.E. (2013) Arsenic. Can This Toxic Metalloid Sustain Life? Metal Ions in Life Sciences, 13, 475-498.  
&lt;br&gt;https://doi.org/10.1007/978-94-007-7500-8_15</mixed-citation></ref><ref id="hanspub.21124-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Jeong, Y.M., Oh, W.K., Tran, T.L., et al. (2013) Aglycone of Rh4 Inhibits Melanin Synthesis in B16 Melanoma Cells: Possible Involvement of the Protein Kinase a Pathway. Bioscience, Biotechnology, and Biochemistry, 77, 119-125.  
&lt;br&gt;https://doi.org/10.1271/bbb.120602</mixed-citation></ref><ref id="hanspub.21124-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Xu, Y., Ji, W., et al. (2014) Anti-Tumor Activities of Matrine and Oxymatrine: Literature Review. Tumor Biology, 35, 5111-5119. &lt;br&gt;https://doi.org/10.1007/s13277-014-1680-z</mixed-citation></ref><ref id="hanspub.21124-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Fan, J.M., Liu, Z.H., Li, J., et al. (2013) Effect of Ginseng Polysaccharide-Induced Wnt/Beta-Catenin Signal Transduction Pathway on Apoptosis of Human Nasopharyngeal Cancer Cells CNE-2. Zhongguo Zhong Yao Za Zhi, 38, 3332-3327.</mixed-citation></ref><ref id="hanspub.21124-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, S., Zhang, Y., Zhuang, Y., et al. (2012) Matrine Induces Apoptosis in Human Acute Myeloid Leukemia Cells via the Mitochondrial Pathway and Akt Inactivation. PLoS One, 7, Article ID: e46853.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0046853</mixed-citation></ref><ref id="hanspub.21124-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wu, D., Shao, K., Sun, J., et al. (2014) Matrine Cooperates with All-Trans Retinoic Acid on Differentiation Induction of All-Trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cells (NB4-LR1): Possible Mechanisms. Planta Medica, 80, 399-408. &lt;br&gt;https://doi.org/10.1055/s-0034-1368183</mixed-citation></ref><ref id="hanspub.21124-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wild, J., Schmiedel, B.J., Maurer, A., et al. (2015) Neutralization of NK Cell-Derived B Cell Activating Factor by Belimumab Restores Sensitivity of Chronic Lymphoid Leukemia Cells to Direct and Rituximab-Induced NK Lysis. Leukemia, 29, 1676. &lt;br&gt;https://doi.org/10.1038/leu.2015.50</mixed-citation></ref><ref id="hanspub.21124-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Jain, P., Lee, H.J., Qiao, W., et al. (2014) FCR and Bevacizumab Treatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Cancer, 120, 3494-3501. &lt;br&gt;https://doi.org/10.1002/cncr.28910</mixed-citation></ref><ref id="hanspub.21124-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tarlock, K., Chang, B., Cooper, T., et al. (2015) Sorafenib Treatment Following Hematopoietic Stem Cell Transplant in Pediatric FLT3/ITD Acute Myeloid Leukemia. Pediatr Blood Cancer, 62, 1048. &lt;br&gt;https://doi.org/10.1002/pbc.25437</mixed-citation></ref><ref id="hanspub.21124-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bhatia, A., Kanish, B. and Chaudhary, P. (2015) Lichenoid Drug Eruption due to Imatinib Mesylate. International Journal of Applied and Basic Medical Research, 5, 68-69. &lt;br&gt;https://doi.org/10.4103/2229-516X.149253</mixed-citation></ref><ref id="hanspub.21124-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Xiang, D., Shigdar, S., Qiao, G., et al. (2015) Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: The Next Generation of Cancer Medicine. Theranostics, 5, 23-42. &lt;br&gt;https://doi.org/10.7150/thno.10202</mixed-citation></ref><ref id="hanspub.21124-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kim, M. and Costello, J. (2017) DNA Methylation: An Epigenetic Mark of Cellular Memory. Experimental and Molecular Medicine, 49, Article ID: e322. &lt;br&gt;https://doi.org/10.1038/emm.2017.10</mixed-citation></ref><ref id="hanspub.21124-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Amabile, G., Di, R.A., Müller, F., et al. (2015) Dissecting the Role of Aberrant DNA Methylation in Human Leukaemia. Nature Communications, 6, 7091. &lt;br&gt;https://doi.org/10.1038/ncomms8091</mixed-citation></ref><ref id="hanspub.21124-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Momparler, R.L., Côté, S., Momparler, L.F., et al. (2017) Inhibition of DNA and Histone Methylation by 5-Aza-2'- Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells. Frontiers in Oncology, 7, 19. &lt;br&gt;https://doi.org/10.3389/fonc.2017.00019</mixed-citation></ref><ref id="hanspub.21124-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Gatla, H.R., Zou, Y., Uddin, M.M., et al. (2017) Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-Dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. Journal of Biological Chemistry, 292, 5043-5054. &lt;br&gt;https://doi.org/10.1074/jbc.M116.771014</mixed-citation></ref><ref id="hanspub.21124-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">D'Amato, L., Dell'Aversana, C., Conte, M., et al. (2015) ARHGEF3 Controls HDACi-Induced Differentiation via RhoA-Dependent Pathways in Acute Myeloid Leukemias. Epigenetics, 10, 6-18.  
&lt;br&gt;https://doi.org/10.4161/15592294.2014.988035</mixed-citation></ref><ref id="hanspub.21124-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mummaneni, P. and Shord, S.S. (2014) Epigenetics and Oncology. Pharmacotherapy, 34, 495-505.  
&lt;br&gt;https://doi.org/10.1002/phar.1408</mixed-citation></ref><ref id="hanspub.21124-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Li, C., Tao, Y., Li, C., et al. (2016) PU.1-Bim Axis Is Involved in Trichostatin A-Induced Apoptosis in Murine Pro-B Lymphoma FL5.12 Cells. Acta Biochimica et Biophysica Sinica (Shanghai), 48, 850-855.  
&lt;br&gt;https://doi.org/10.1093/abbs/gmw067</mixed-citation></ref><ref id="hanspub.21124-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Ni, Z., Duan, Z., et al. (2015) Overexpression of E2F MRNAs Asso-ciated with Gastric Cancer Progression Identified by the Transcription Factor and MiRNA Co-Regulatory Network Analysis. PLoS One, 10, Article ID: e0116979. &lt;br&gt;https://doi.org/10.1371/journal.pone.0116979</mixed-citation></ref><ref id="hanspub.21124-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Brauer-Hartmann, D., Hartmann, J.U., Wurm, A.A., et al. (2015) PML/RARα-Regulated MiR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Research, 75, 3411-3424.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-14-3521</mixed-citation></ref><ref id="hanspub.21124-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">McCulloch, D., Brown, C. and Iland, H. (2017) Retinoic Acid and Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia: Current Perspectives. Oncotargets and Therapy, 10, 1585-1601.  
&lt;br&gt;https://doi.org/10.2147/OTT.S100513</mixed-citation></ref><ref id="hanspub.21124-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Atashrazm, F., Lowenthal, R.M., Dickinson, J.L., et al. (2016) Fucoidan Enhances the Therapeutic Potential of Arsenic Trioxide and All-Trans Retinoic Acid in Acute Promyelocytic Leukemia, in Vitro and in Vivo. Oncotarget, 7, 46028- 46041.</mixed-citation></ref></ref-list></back></article>